Navigation Links
Bullet Bio Provides Update On Recent Financing And Results From Proof-Of-Concept Study For Lead Product Candidate
Date:9/12/2013

tions, where a finely targeted, personalized immunotherapy can be used instead of the carpet-bombing chemotherapy approach. We're working very hard to start clinical trials in 2015 to demonstrate the safety and efficacy of our product and ultimately get to patients as quickly as we can," said Willie Quinn, President & CEO of Bullet Bio.

About Active Immunotherapy in B-Cell Lymphomas

In 2013, nearly 70,000 patients will be diagnosed in the US and Europe with incurable B-cell lymphomas, including Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin Lymphoma.  More than 60% of CLL patients are asymptomatic when diagnosed, and the standard of care is to observe these patients until the severity of symptoms warrants treatment. Although modern drugs, including antibodies and kinase inhibitors, improve outcomes, mortality for B-cell lymphomas remains high. Standard treatment often leads to chemotherapy and is accompanied by infection, bleeding, fatigue and other side effects.

Bullet Bio is working to develop an active immunotherapy that would be safe enough to be given to asymptomatic patients and powerful enough to change the course of their disease by harnessing the power of their own immune system.

About Bullet Biotechnology

Bullet Biotechnology, Inc. is a privately-held biotechnology company researching and developing active immunotherapies for patients with cancers and autoimmune diseases. Bullet Bio's lead product, BB-001, is a fully personalized active immunotherapy that uses a unique marker on B-cell lymphoma cells, the idiotype protein, to train a patient's own immune system to target their cancer cells.


'/>"/>
SOURCE Bullet Biotechnology
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Questcor Comments on Insurance Policy Bulletin
2. SafeCode Drug Technologies Corp. Begins Trading on the Over-the-Counter Bulletin Board
3. Groupe Athena, Inc. Reports Record First Quarter Revenues, Adoption Of IFRS Accounting Standard In Anticipation Of Applying For Listing On The NASDAQ Bulletin Board
4. MetaStat Announces Stock Trading on OTC Bulletin Board
5. MediPendant™ to Return to Television on May 20th New Television Campaign - Company Provides MediPendant™ Update
6. Anthera Pharmaceuticals Reports 2012 First Quarter Financial Results And Provides Clinical Progress Update
7. Regeneron Provides Update On FDA Advisory Committee Discussion of ARCALYST® (rilonacept) Injection
8. Simcere Pharmaceutical Group Provides Notice of Annual General Meeting
9. Elevate Provides Remote Access to Personal Health Records Using MyMedicalRecords.com
10. Health Diagnostic Laboratory, Inc. Provides Grant to Support National Lipid Association, Sponsors 2012 Annual Scientific Sessions in Scottsdale, Arizona
11. NexGen Biomedical, Inc. Provides New Insights Into Jett Travoltas Seizure Related Death
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... , Sept. 29, 2014 Pharmaceutical Care Management ... today outlined policy solutions that could reduce prescription fraud ... Hill briefing, " Prescription Opioid Abuse: Fighting Back on ... Reform and PCMA. The briefing featured ... prescription drug abuse and fraud. The Centers for Disease ...
(Date:9/29/2014)... , Sept. 29, 2014 EU5 Sigmoidoscopes ... new report, "EU5 Sigmoidoscopes Market Outlook to 2020", ... market. The report provides value, in millions of ... (in US dollars) within market segments - Flexible ... and Flexible Non-Video (Fibre) Sigmoidoscopes). The ...
(Date:9/29/2014)... SAN DIEGO , 29 de septiembre de 2014 ... adelante, Daiichi Sankyo) (TSE: 4568) y Ambit Biosciences (NASDAQ: ... que han llegado a un acuerdo de fusión definitivo ... acciones ordinarias de Ambit Biosciences a un precio de ... una oferta de licitación seguida de una fusión con ...
Breaking Medicine Technology:PCMA: How Congress Can Fight Prescription Drug Fraud and Abuse 2EU5 Sigmoidoscopes Market Outlook to 2020 2EU5 Sigmoidoscopes Market Outlook to 2020 3Daiichi Sankyo adquiere Ambit Biosciences 2Daiichi Sankyo adquiere Ambit Biosciences 3Daiichi Sankyo adquiere Ambit Biosciences 4Daiichi Sankyo adquiere Ambit Biosciences 5Daiichi Sankyo adquiere Ambit Biosciences 6Daiichi Sankyo adquiere Ambit Biosciences 7Daiichi Sankyo adquiere Ambit Biosciences 8
... safety profile of BSI-201 in ... subjects with advanced solid tumors -, BRISBANE, Calif., ... developing novel cancer therapies,today announced that data supporting its lead ... of Clinical Oncology annual,meeting in Chicago., Findings will be ...
... SGP ), a leader in advancing the ... infection, announced today that data from,several clinical studies ... therapy, as well as boceprevir, the,company,s investigational oral ... annual Digestive Disease Week (DDW) meeting to be ...
Cached Medicine Technology:BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting 2Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 2Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 3Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 4Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 5Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 6Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 7
(Date:9/30/2014)... CA (PRWEB) September 30, 2014 ... now offering gum depigmentation treatments for dark gums. Dark ... can make people feel extremely self-conscious about their smiles. ... or dark gums. “I am one of the few ... and I have treated celebrities, business leaders, high-ranking officials ...
(Date:9/30/2014)... In books and movies, plots involving older men chasing ... suggests that the stereotype may be grounded in fact. ... than 12,000 people from Finland. The researchers, led by ... women typically preferred men who were the same age or ... On the other hand, men tended to have a lifelong ...
(Date:9/30/2014)... Sept. 30, 2014 (HealthDay News) -- For millions of ... excess weight and the threat of type 2 diabetes. ... may be tougher for some than for others, depending ... good health, it may not be as effective for ... 2 diabetes," said one expert, Dr. Ruth Loos, director ...
(Date:9/30/2014)... University of Michigan have described a new approach to ... the time needed for more traditional methods. , ... that is undergoing further investigation as a potential treatment ... , In research published online in the Proceedings ... the lab of Stephen Weiss at the U-M Life ...
(Date:9/30/2014)... Missouri (PRWEB) September 30, 2014 The ... that the SLUCare Physician Group, comprised of more than ... on a number of initiatives. With the recent ... network size, strengthening its market footprint to better respond ... Louis area. , SLPA is a physician-led clinically integrated ...
Breaking Medicine News(10 mins):Health News:Gummy Smile Dentist, Dr. Alex Farnoosh, is Now Offering Gum Depigmentation for Dark Gums 2Health News:When It Comes to Sex Partners, Men Prefer Younger Women: Study 2Health News:Can Exercise Prevent Type 2 Diabetes? Your Genes May Be Key 2Health News:New discovery approach accelerates identification of potential cancer treatments 2Health News:St. Louis Physician Alliance Expands Network and Market Footprint with Recent Addition of SLUCare Physician Group 2
... men has increased by 12% in six years, according to the ... diagnosed with the disease, 3,000 of those are men.// ... that they tend to occur more commonly on the back, whereas ... noticeable. Up to 77% of cases are caused by exposure to ...
... a mother's risk of having a hyperactive child. A ... the last three months of pregnancy had children with ... Glover, of Imperial College, London, told that this only ... frequently feeling scared.According to a survey antenatal anxiety ...
... somebody is likely to have an epileptic seizure. ,In ... warning and can lead to ,disability or even death. ... believe ,it may be possible to predict the onset ... ,An ECG records electrical activity from different parts of ...
... years. And while most of the popular remedies used in ... has increased. This powerful pill will //reduce pain, fever, inflammation, ... attacks and stroke. ,In the more than 35 ... few drugs have been developed that can even be compared ...
... one day have the option of having one blast ... up to 25 sessions afterwards, researchers said. //They believe ... for women and may improve the treatment of breast ... the developing world. ,Dr. Emiel Rutgers, of the ...
... new compounds developed for preventing and treating the flue ... only one dose to be effective.// The compounds, known ... flu drug relenza, or zanamivir, which the U.S. Food ... A and B. ,Researchers reported at the International ...
Cached Medicine News:
The 5539-7.5 linear transducer is a high frequency transducer dedicated to superficial and vascular imaging....
HST, versatile convex array abdominal transducer is multi-frequency, offering 5 levels of fundamental frequencies in addition to 4 settings of Harmonic frequencies. This transducer provides superb im...
Scan internal organs percutaneously while eliminating side lobe artifact....
... transducer is a curved ... the higher frequencies. Featuring ... this transducer provides exceptional ... frequency abdominal kidney bladder ...
Medicine Products: